Matthew A Silva
Affiliation: Massachusetts College of Pharmacy and Health Sciences
- Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?M A Silva
Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Worcester, MA 01608, USA
J Clin Pharm Ther 29:497-510. 2004....
- Statin-related adverse events: a meta-analysisMatthew A Silva
Massachusetts College of Pharmacy and Health Sciences, Worcester, Massachusetts 01608, USA
Clin Ther 28:26-35. 2006..The absolute frequencies of adverse events (AEs) between statins and placebo are very low in clinical trials, making clinical interpretation and application difficult...
- Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?Matthew A Silva
Massachusetts College of Pharmacy and Health Sciences, Department of Pharmacy Practice, 19 Foster Street, Worcester, MA 01608, USA
Vasc Health Risk Manag 2:39-48. 2006..These new data will impact emerging guidelines and updates are currently in progress...
- HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive proteinKristine Y Chan
St Luke s Medical Center, Milwaukee, WI, USA
Am J Health Syst Pharm 61:1676-81. 2004..Clinical trials evaluating the effectiveness of therapy with hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors for reducing elevated C-reactive protein (CRP) levels and associated coronary events are reviewed...